Valganciclovir Hydrochloride Patent Expiration
Valganciclovir Hydrochloride is Used for preventing CMV disease in high-risk kidney, heart, and kidney-pancreas transplant patients. It was first introduced by Cheplapharm Arzneimittel Gmbh
Valganciclovir Hydrochloride Patents
Given below is the list of patents protecting Valganciclovir Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Valcyte | US6083953 | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Mar 29, 2015
(Expired) | Cheplapharm |
| Valcyte |
US6083953 (Pediatric) | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Sep 29, 2015
(Expired) | Cheplapharm |
| Valcyte | US8889109 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | Dec 11, 2027 | Cheplapharm |
| Valcyte | US9642911 | Pharmaceutical dosage forms comprising valganciclovir hydrochloride | Dec 11, 2027 | Cheplapharm |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Valganciclovir Hydrochloride's patents.
Latest Legal Activities on Valganciclovir Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Valganciclovir Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 30 Aug, 2022 | US9642911 |
| Change in Power of Attorney (May Include Associate POA) Critical | 30 Aug, 2022 | US9642911 |
| Correspondence Address Change Critical | 26 Aug, 2022 | US9642911 |
| Change in Power of Attorney (May Include Associate POA) Critical | 25 Aug, 2022 | US8889109 |
| Correspondence Address Change Critical | 24 Aug, 2022 | US8889109 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Apr, 2022 | US8889109 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9642911 |
| Surcharge for Late Payment, Large Entity | 21 Aug, 2018 | US8889109 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Aug, 2018 | US8889109 |
| Maintenance Fee Reminder Mailed Critical | 02 Jul, 2018 | US8889109 |
Try Our Curated Drug Screens
Valganciclovir Hydrochloride Generics
Several generic applications have been filed for Valganciclovir Hydrochloride. The first generic version for Valganciclovir Hydrochloride was by Strides Pharma Global Pte Ltd and was approved on Nov 4, 2014. And the latest generic version is by Gpp Consortium Llc and was approved on Jun 11, 2024.
Given below is the list of companies who have filed for Valganciclovir Hydrochloride generic.
1. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/ML | for solution | Prescription | ORAL | AB | Jul 18, 2016 |
2. AJANTA PHARMA LTD
Ajanta Pharma Ltd has filed for 2 different strengths of generic version for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Prescription | ORAL | AB | Dec 26, 2019 |
| 50MG/ML | for solution | Prescription | ORAL | AB | Jan 13, 2020 |
3. APPCO
Appco Pharma Llc has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Appco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/ML | for solution | Prescription | ORAL | AB | Apr 11, 2023 |
4. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/ML | for solution | Prescription | ORAL | AB | Nov 17, 2022 |
5. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Prescription | ORAL | AB | Mar 31, 2016 |
6. CIPLA
Cipla Ltd has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Cipla.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Discontinued | ORAL | N/A | Nov 9, 2018 |
7. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Prescription | ORAL | AB | Dec 12, 2017 |
8. GPP
Gpp Consortium Llc has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Gpp.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Prescription | ORAL | AB | Jun 11, 2024 |
9. GRANULES
Granules Pharmaceuticals Inc has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Granules.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/ML | for solution | Prescription | ORAL | AB | Jan 31, 2020 |
10. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 2 different strengths of generic version for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Prescription | ORAL | AB | Mar 18, 2016 |
| 50MG/ML | for solution | Prescription | ORAL | AB | Oct 4, 2022 |
11. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 50MG/ML | for solution | Prescription | ORAL | AB | Feb 17, 2022 |
12. NORVIUM BIOSCIENCE
Norvium Bioscience Llc has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Discontinued | ORAL | N/A | Mar 3, 2021 |
13. STRIDES PHARMA
Strides Pharma Global Pte Ltd has filed for 1 generic for Valganciclovir Hydrochloride. Given below are the details of the strengths of this generic introduced by Strides Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 450MG BASE | tablet | Prescription | ORAL | AB | Nov 4, 2014 |